AMLX
Price
$18.41
Change
+$0.82 (+4.66%)
Updated
Jul 24, 04:59 PM (EDT)
Capitalization
1.95B
13 days until earnings call
Intraday BUY SELL Signals
CRVS
Price
$13.07
Change
-$0.61 (-4.46%)
Updated
Jul 24, 04:59 PM (EDT)
Capitalization
1.15B
18 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

AMLX vs CRVS

AMLX vs CRVS Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
AMLX vs. CRVS commentary
Jul 25, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMLX is a Hold and CRVS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 25, 2026
Stock price -- (AMLX: $17.59 vs. CRVS: $13.68)
Brand notoriety: AMLX and CRVS are both not notable
AMLX represents the Pharmaceuticals: Generic, while CRVS is part of the Biotechnology industry
Current volume relative to the 65-day Moving Average: AMLX: 36% vs. CRVS: 45%
Market capitalization -- AMLX: $1.95B vs. CRVS: $1.15B
AMLX [@Pharmaceuticals: Generic] is valued at $1.95B. CRVS’s [@Biotechnology] market capitalization is $1.15B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The market cap for tickers in the [@Biotechnology] industry ranges from $120.07B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.02B. The average market capitalization across the [@Biotechnology] industry is $2.09B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AMLX’s FA Score shows that 0 FA rating(s) are green whileCRVS’s FA Score has 0 green FA rating(s).

  • AMLX’s FA Score: 0 green, 5 red.
  • CRVS’s FA Score: 0 green, 5 red.
According to our system of comparison, AMLX is a better buy in the long-term than CRVS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AMLX’s TA Score shows that 5 TA indicator(s) are bullish while CRVS’s TA Score has 5 bullish TA indicator(s).

  • AMLX’s TA Score: 5 bullish, 5 bearish.
  • CRVS’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, both AMLX and CRVS are a good buy in the short-term.

Price Growth

AMLX (@Pharmaceuticals: Generic) experienced а +3.35% price change this week, while CRVS (@Biotechnology) price change was -4.13% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +5.02%. For the same industry, the average monthly price growth was +3.40%, and the average quarterly price growth was +12.87%.

The average weekly price growth across all stocks in the @Biotechnology industry was -4.69%. For the same industry, the average monthly price growth was -3.66%, and the average quarterly price growth was +1910.60%.

Reported Earning Dates

AMLX is expected to report earnings on Aug 06, 2026.

CRVS is expected to report earnings on Aug 11, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (+5.02% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

@Biotechnology (-4.69% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AMLX($1.96B) has a higher market cap than CRVS($1.15B). CRVS YTD gains are higher at: 77.662 vs. AMLX (45.613). CRVS has higher annual earnings (EBITDA): -47.81M vs. AMLX (-158.8M). AMLX has more cash in the bank: 280M vs. CRVS (237M). CRVS has less debt than AMLX: CRVS (834K) vs AMLX (5.63M). AMLX (0) and CRVS (0) have equivalent revenues.
AMLXCRVSAMLX / CRVS
Capitalization1.96B1.15B170%
EBITDA-158.8M-47.81M332%
Gain YTD45.61377.66259%
P/E Ratio2.69N/A-
Revenue00-
Total Cash280M237M118%
Total Debt5.63M834K675%
FUNDAMENTALS RATINGS
CRVS: Fundamental Ratings
CRVS
OUTLOOK RATING
1..100
87
VALUATION
overvalued / fair valued / undervalued
1..100
71
Overvalued
PROFIT vs RISK RATING
1..100
58
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
39
P/E GROWTH RATING
1..100
98
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
AMLXCRVS
RSI
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
74%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 2 days ago
83%
Momentum
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
88%
MACD
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
88%
Advances
ODDS (%)
Bullish Trend 29 days ago
79%
Bullish Trend 16 days ago
82%
Declines
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
80%
Aroon
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
AMLX
Daily Signal:
Gain/Loss:
CRVS
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
TCAI50.700.25
+0.50%
Tortoise AI Infrastructure ETF
DECZ43.17N/A
N/A
TrueShares Structured Outcome Dec ETF
FGD33.79-0.20
-0.59%
First Trust Dow Jones Global Sel Div ETF
RWX27.37-0.23
-0.83%
State Street® SPDR® Dow Jones® IntlREETF
ITDJ32.20-0.39
-1.21%
iShares LifePath Target Date 2070 ETF

CRVS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRVS has been closely correlated with ACRS. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if CRVS jumps, then ACRS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRVS
1D Price
Change %
CRVS100%
-2.22%
ACRS - CRVS
68%
Closely correlated
-2.49%
RZLT - CRVS
42%
Loosely correlated
+6.20%
AMLX - CRVS
36%
Loosely correlated
-0.62%
OVID - CRVS
35%
Loosely correlated
+0.84%
IMNM - CRVS
35%
Loosely correlated
-3.80%
More